In today's edition, health-care editor David Williamson checks up on Arena Pharmaceuticals. Arena has gone on quite a run over the past seven months, and its 400% year-to-date growth makes it one of the sector's top performers. How did Arena get here, and how will it close out 2011? Watch and find out.
Arena's revolutionary obesity treatment Belviq isn't the only disruptive event invesotrs can profit from. The Motley Fool has just released a free report on mobile named "The Next Trillion-Dollar Revolution" that details a hidden component play inside mobile phones that also is a market leader in the exploding Chinese market. Inside the report, we not only describe why the mobile revolution will dwarf any other technology revolution seen before it, but we also name the company at the forefront of the trend. Hundreds of thousands have requested access to previous reports, and you can access this new report today by clicking here -- it's free.
The article Midyear Review: Arena Pharmaceuticals originally appeared on Fool.com.
Dave Williamson and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.